Hunan Jingfeng Pharmaceutical Co.,Ltd.

SZSE:000908 Stock Report

Market Cap: CN¥4.2b

Hunan Jingfeng PharmaceuticalLtd Balance Sheet Health

Financial Health criteria checks 2/6

Hunan Jingfeng PharmaceuticalLtd has a total shareholder equity of CN¥-260.4M and total debt of CN¥567.8M, which brings its debt-to-equity ratio to -218%. Its total assets and total liabilities are CN¥1.0B and CN¥1.3B respectively.

Key information

-218.0%

Debt to equity ratio

CN¥567.77m

Debt

Interest coverage ration/a
CashCN¥21.65m
Equity-CN¥260.40m
Total liabilitiesCN¥1.28b
Total assetsCN¥1.02b

Recent financial health updates

No updates

Recent updates

The Market Doesn't Like What It Sees From Hunan Jingfeng Pharmaceutical Co.,Ltd.'s (SZSE:000908) Revenues Yet As Shares Tumble 27%

Jun 13
The Market Doesn't Like What It Sees From Hunan Jingfeng Pharmaceutical Co.,Ltd.'s (SZSE:000908) Revenues Yet As Shares Tumble 27%

Hunan Jingfeng Pharmaceutical Co.,Ltd.'s (SZSE:000908) 31% Dip In Price Shows Sentiment Is Matching Revenues

Apr 16
Hunan Jingfeng Pharmaceutical Co.,Ltd.'s (SZSE:000908) 31% Dip In Price Shows Sentiment Is Matching Revenues

Hunan Jingfeng Pharmaceutical Co.,Ltd.'s (SZSE:000908) 26% Dip In Price Shows Sentiment Is Matching Revenues

Feb 29
Hunan Jingfeng Pharmaceutical Co.,Ltd.'s (SZSE:000908) 26% Dip In Price Shows Sentiment Is Matching Revenues

Financial Position Analysis

Short Term Liabilities: 000908 has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: 000908 has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: 000908 has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: 000908's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable 000908 has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: 000908 is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 13.6% per year.


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 02:50
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Hunan Jingfeng Pharmaceutical Co.,Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Guohe FanPhillip Securities (HK)
Yin YePing An Securities Co. Ltd.